Manual therapy and exercise vs placebo
Quality of life · rotator cuff disease
1 finding from 1 review
- no estimate extracted1 study · 120 participantsHigh
Findings
What do systematic reviews say?
280 questions · 282 findings · 22 reviews · Musculoskeletal
No studies found 87 · 30.9%GRADE not reported 5 · 1.8%Very low 43 · 15.2%Low 94 · 33.3%Moderate 35 · 12.4%High 18 · 6.4%
Manual therapy and exercise vs placebo
Adverse events · rotator cuff disease
Manual therapy and exercise leads to higher adverse events compared with placebo (high certainty).
1 finding from 1 review
- RR 3.77 [1.49, 9.54]1 study · 116 participantsHigh
Manual therapy and exercise vs glucocorticoid injection
Overall pain · rotator cuff disease
1 finding from 1 review
- no estimate extracted1 study · 88 participantsLow
Manual therapy and exercise vs glucocorticoid injection
Function · rotator cuff disease
1 finding from 1 review
- no estimate extracted1 study · 88 participantsLow
Manual therapy and exercise vs glucocorticoid injection
Pain on motion · rotator cuff disease
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in remission (number of patients with remission) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.97 [0.89, 1.07]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Durable remission · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in durable remission compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.93 [0.77, 1.11]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Major relapse · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in major relapse compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 2.94 [0.12, 70.67]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Disease flare · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in disease flare compared with standard therapy with placebo (moderate certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 0.98 [0.76, 1.27]Studies not reportedModerate
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Any adverse event · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any adverse event compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1.12 [0.97, 1.29]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Any severe or serious AE (grade 3, 4 or 5) · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in any severe or serious AE (grade 3, 4 or 5) compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 1 [0.8, 1.27]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
Withdrawals due to adverse events · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy may leads to higher any withdrawals due to AE compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyRR 2.66 [1.07, 6.59]Studies not reportedLow
Active drug (etanercept or belimumab) with standard therapy vs placebo + standard care
MortalityNumber of participants: 285(2 RCTs) WGET 2005 · adults (age 18 years and older) with GPA ANCA‐associated vasculitis or microscopic polyangiitis (only a subset of patients in one study,…
Active drug (etanercept or belimumab) with standard therapy showed no clear difference in mortalityNumber of participants: 285(2 RCTs) WGET 2005 compared with standard therapy with placebo (low certainty).
1 finding from 1 review
- Anti‐cytokine targeted therapies for ANCA‐associated vasculitis 2020 · Cochrane Headline outcomes onlyPeto OR 2.45 [0.55, 10.97]Studies not reportedLow
Low‐level laser therapy vs placebo
Participant‐reported pain relief of 30% or greater · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
- Electrotherapy modalities for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low‐level laser therapy vs placebo
Overall pain · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
- Electrotherapy modalities for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low‐level laser therapy vs placebo
Function · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
- Electrotherapy modalities for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low‐level laser therapy vs placebo
Global assessment of treatment success · patients with adhesive capsulitis (frozen shoulder)
Low‐level laser therapy (LLLT) may leads to higher global assessment of treatment success 'Excellent' or 'good' result… compared with placebo (low certainty).
1 finding from 1 review
- Electrotherapy modalities for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes onlyRR 8 [2.11, 30.34]1 study · 40 participantsLow
Low‐level laser therapy vs placebo
Active shoulder abduction · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
- Electrotherapy modalities for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low‐level laser therapy vs placebo
Quality of life · patients with adhesive capsulitis (frozen shoulder)
The review found no eligible studies for this question.
1 finding from 1 review
- Electrotherapy modalities for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found
Low‐level laser therapy vs placebo
Adverse events · patients with adhesive capsulitis (frozen shoulder)
1 finding from 1 review
- Electrotherapy modalities for adhesive capsulitis (frozen shoulder) 2014 · Cochrane Headline outcomes onlyno estimate extracted1 study · 40 participantsLow